PMC / PIMCO Municipal Credit Income Fund - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

PMC / PharMerica Corp. 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-33380 PharMerica Corporation (Exact name of registrant as specified in i

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 19, 2017, pursuant to the provisions of Rule 12d2-2 (a).

PMC / PharMerica Corp. S-8 POS

Registration No. 333-145137 Registration No. 333-195971 Registration No. 333-206452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145137 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-195971 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-206452 R

PMC / PharMerica Corp. S-8 POS

Registration No. 333-145137 Registration No. 333-195971 Registration No. 333-206452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145137 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-195971 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-206452 R

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emp

PHARMERICA CORPORATION AMENDED AND RESTATED ADOPTED DECEMBER 7, 2017 ARTICLE I MEETINGS OF STOCKHOLDERS

Exhibit 3.2 PHARMERICA CORPORATION AMENDED AND RESTATED BY-LAWS ADOPTED DECEMBER 7, 2017 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meeting and Notice. Meetings of the stockholders of the Corporation shall be held at such place either within or without the State of Delaware as the Board of Directors may determine. Section 2. Annual and Special Meetings. Annual meetings of stockholders

2

Exhibit 99.1 KKR Completes Acquisition of PharMerica LOUISVILLE, Ky.-(BUSINESS WIRE)?Dec. 7, 2017- PharMerica Corporation (NYSE: PMC) today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor. As a result of the completion of the acquisition, PharMerica shareho

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION PHARMERICA CORPORATION

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PHARMERICA CORPORATION FIRST: The name of the corporation (which is hereinafter referred to as the ?Corporation?) is PharMerica Corporation. SECOND: The registered office of the Corporation in the State of Delaware is located at 4001 Kennett Pike, Suite 302, County of New Castle, Wilmington, DE 19807, and the name of the registered a

PMC / PharMerica Corp. S-8 POS

Registration No. 333-145137 Registration No. 333-195971 Registration No. 333-206452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145137 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-195971 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-206452 R

PHARMERICA REPORTS THIRD QUARTER 2017 RESULTS PharMerica Stockholders Approve Merger at Special Meeting; Transaction On-Track to Close by Early 2018

Exhibit 99.1 Contact: Robert E. Dries Executive Vice President and Chief Financial Officer (502) 627-7140 PHARMERICA REPORTS THIRD QUARTER 2017 RESULTS PharMerica Stockholders Approve Merger at Special Meeting; Transaction On-Track to Close by Early 2018 LOUISVILLE, Ky. (November 9, 2017) – PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica Announces Approval of Merger by Stockholders

Exhibit 99.1 PharMerica Announces Approval of Merger by Stockholders LOUISVILLE, Ky.-(BUSINESS WIRE)-Nov. 9, 2017- PharMerica Corporation (NYSE: PMC), announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMerica common stock voted to approve the adoption of the previously disclosed definitive merger agreement pursuant to which a newly formed

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emp

PMC / PharMerica Corp. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emp

PharMerica FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

PharMerica DEFM14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?o Check the appropriate box: ?o Preliminary Proxy Statement ?o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D

PharMerica PREM14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?o Check the appropriate box: ? Preliminary Proxy Statement ?o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?o D

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Empl

PharMerica FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Empl

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emplo

Antitrust Support Side Letter among PharMerica Corporation, KKR Americas Fund XII L.P. and Walgreens Boots Alliance, Inc. dated as of August 1, 2017 (1)

EXHIBIT 2.2 August 1, 2017 PharMerica Corporation 1901 Campus Place Louisville, KY 40299 Re: Antitrust Support Side Letter Ladies and Gentlemen: Reference is made to the Agreement and Plan of Merger (the ?Merger Agreement?), dated as of the date hereof, between PharMerica Corporation (the ?Company?), Phoenix Parent Holdings Inc. (?Parent?) and Phoenix Merger Sub Inc. Capitalized terms used herein

Agreement and Plan of Merger among PharMerica Corporation, Phoenix Parent Holdings Inc. and Phoenix Merger Sub Inc. dated as of August 1, 2017 (1)

EXHIBIT 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of August 1, 2017 among PharMerica Corporation, Phoenix Parent Holdings Inc. and Phoenix Merger Sub Inc. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 6 Section 1.02. Other Definitional and Interpretative Provisions 15 ARTICLE 2 [INTENTIONALLY OMITTED] ARTICLE 3 THE MERGER Section 3.01. The Merger 15 Secti

[Signature page follows]

EXHIBIT 2.2 August 1, 2017 PharMerica Corporation 1901 Campus Place Louisville, KY 40299 Re: Antitrust Support Side Letter Ladies and Gentlemen: Reference is made to the Agreement and Plan of Merger (the ?Merger Agreement?), dated as of the date hereof, between PharMerica Corporation (the ?Company?), Phoenix Parent Holdings Inc. (?Parent?) and Phoenix Merger Sub Inc. Capitalized terms used herein

PharMerica FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emplo

AGREEMENT AND PLAN OF MERGER dated as of August 1, 2017 among PharMerica Corporation, Phoenix Parent Holdings Inc. and Phoenix Merger Sub Inc. TABLE OF CONTENTS

EXHIBIT 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of August 1, 2017 among PharMerica Corporation, Phoenix Parent Holdings Inc. and Phoenix Merger Sub Inc. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 6 Section 1.02. Other Definitional and Interpretative Provisions 15 ARTICLE 2 [INTENTIONALLY OMITTED] ARTICLE 3 THE MERGER Section 3.01. The Merger 15 Secti

Dear PharMerica Associates:

Exhibit 99.2 Dear PharMerica Associates: This morning we announced that PharMerica has entered into an agreement to be acquired by a newly formed company controlled by KKR, with Walgreens Boots Alliance as a minority investor. PharMerica?s leadership and management will remain unchanged. This change will significantly enhance our ability to develop and rapidly scale new products and services. This

As leaders at PharMerica, you will play an important role in setting the right tone from the outset and communicating with our employees at all levels of the organization. Attached you will find a copy of the following communications materials regard

Exhibit 99.4 To: PharMerica Senior Leaders Re: Communications Toolkit As detailed in the press release, PharMerica has entered into an agreement to be acquired by a newly formed company controlled by KKR, a leading private equity firm, with Walgreens Boots Alliance as a minority investor. We are excited about this partnership, which will deliver substantial benefits to our clients and employees. A

CLIENT LETTER

Exhibit 99.1 CLIENT LETTER Dear [INSERT CLIENT], PharMerica announced this morning that it has entered into an agreement to be acquired by a newly formed company controlled by Kohlberg, Kravis and Roberts (KKR), a leading private equity firm, with Walgreens Boots Alliance, a world leader in pharmaceutical services, as a minority investor. This partnership will significantly enhance our ability to

PharMerica FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Client Talking Points

Exhibit 99.3 Client Talking Points ? As you saw, we recently announced some exciting news about PharMerica. ? PharMerica has entered into an agreement to be acquired by a newly formed company controlled by KKR, with Walgreens Boots Alliance as a minority investor. ? Once the transaction is complete, PharMerica will become a private company. ? Today?s announcement is great news for our clients, cus

Dear Onco360 and CareMed Associates:

Exhibit 99.6 Dear Onco360 and CareMed Associates: This morning PharMerica announced it has entered into an agreement to be acquired by a newly formed company jointly owned by KKR as the majority owner and Walgreens as a minority investor. PharMerica?s leadership will remain unchanged, as will the leadership of its subsidiaries, including Onco360 and CareMed. This change will significantly enhance

Dear Amerita Employees:

Exhibit 99.5 Dear Amerita Employees: This morning PharMerica announced that it has entered into an agreement to be acquired by a newly formed company controlled by KKR, with Walgreens Boots Alliance as a minority owner. This transaction will give PharMerica and its affiliated companies including Amerita enhanced ability to develop and rapidly scale new products, services and infrastructure. These

PHARMERICA REPORTS SECOND QUARTER 2017 RESULTS Separately Announced All-Cash Transaction with KKR and Walgreens Boots Alliance, Inc.

Exhibit 99.1 Contact: Robert E. Dries Executive Vice President and Chief Financial Officer (502) 627-7140 PHARMERICA REPORTS SECOND QUARTER 2017 RESULTS Separately Announced All-Cash Transaction with KKR and Walgreens Boots Alliance, Inc. LOUISVILLE, Ky (August 2, 2017) ? PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharma

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica Corporation Enters into Definitive Agreement to Be Acquired by KKR for $29.25 per Share in Cash Walgreens Boots Alliance, Inc. Will Have Minority Equity Investment in New Company Transaction Valued at Approximately $1.4 Billion

Exhibit 99.1 PharMerica Corporation Enters into Definitive Agreement to Be Acquired by KKR for $29.25 per Share in Cash Walgreens Boots Alliance, Inc. Will Have Minority Equity Investment in New Company Transaction Valued at Approximately $1.4 Billion LOUISVILLE, Ky. - August 2, 2017 - PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospita

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (Commission File Number) (IRS Emplo

PharMerica Corporation Enters into Definitive Agreement to Be Acquired by KKR for $29.25 per Share in Cash Walgreens Boots Alliance, Inc. Will Have Minority Equity Investment in New Company Transaction Valued at Approximately $1.4 Billion

Exhibit 99.1 PharMerica Corporation Enters into Definitive Agreement to Be Acquired by KKR for $29.25 per Share in Cash Walgreens Boots Alliance, Inc. Will Have Minority Equity Investment in New Company Transaction Valued at Approximately $1.4 Billion LOUISVILLE, Ky. - August 2, 2017 - PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospita

PharMerica FORM 8-K

DEFA14A 1 dp791298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 PharMerica Corporation (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State of Incorporation) (C

PMC / PharMerica Corp. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

PharMerica (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS FIRST QUARTER 2017 RESULTS Strong Financial Results Reaffirms Annual 2017 Guidance

Exhibit 99.1 Contact: Robert E. Dries Executive Vice President and Chief Financial Officer (502) 627-7140 PHARMERICA REPORTS FIRST QUARTER 2017 RESULTS Strong Financial Results Reaffirms Annual 2017 Guidance LOUISVILLE, KY (May 10, 2017) ? PharMerica Corporation (the ?Corporation?, PharMerica? or the ?Company?) (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital an

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES SORKIN’S RX LTD. t/a and/or D/B/A CAREMED PHARMACEUTICAL SERVICES

Exhibit 10.1 CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND SORKIN’S RX LTD. t/a and/or D/B/A CAREMED PHARMACEUTICAL SERVICES I. PREAMBLE Sorkin’s Rx Ltd. t/a and/or d/b/a CareMed Pharmaceutical Services (CareMed) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the Un

PharMerica DEF 14A

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under 240.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission F

AMENDED AND RESTATED BY-LAWS PHARMERICA CORPORATION As Amended March 24, 2017 ARTICLE I

Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF PHARMERICA CORPORATION As Amended March 24, 2017 ARTICLE I Stockholders Section 1.01. Annual Meetings. The annual meeting of the stockholders of the Corporation for the election of Directors and for the transaction of such other business as properly may come before such meeting shall be held at such place, either within or without the State of Delaware,

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission F

PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2016 RESULTS Delivers Strong Sequential Growth in Revenues and Earnings in Both Institutional Pharmacy and Diversified Pharmacy Announces Full Year 2017 Guidance

Exhibit 99.1 Contact: Robert Dries Executive Vice President and Chief Financial Officer (502) 627-7950 PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2016 RESULTS Delivers Strong Sequential Growth in Revenues and Earnings in Both Institutional Pharmacy and Diversified Pharmacy Announces Full Year 2017 Guidance LOUISVILLE, Ky . (February 24, 2017) ? PharMerica Corporation (the ?Corporation? or the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

FIRST AMENDMENT TO CREDIT AGREEMENT

Exhibit 10.20 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of December 9, 2016, by and among PHARMERICA CORPORATION, a Delaware corporation (the “Borrower”), the Subsidiary Loan Parties, the Lenders party hereto, THE HUNTINGTON NATIONAL BANK (the “New Lender”) and BANK OF AMERICA, N.A., in its capacity as the Administra

EMPLOYMENT AGREEMENT

Exhibit 10.32 EMPLOYMENT AGREEMENT THIS AGREEMENT by and between PharMerica Corporation and (hereinafter the "Company''), and Robert Dries (the ''Executive") is effective as of January 31, 2017 ("Start Date"); WHEREAS, the Company desires to employ the Executive, effective as of the Start Date, as the Executive Vice President, Chief Financial Officer and Treasurer and the Executive desires to serv

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware OncoMed Specialty, LLC Delaware

to Schedule 13G Joint Filing Agreement

EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 6, 2017 in connection with their beneficial ownership of Pharmerica Corp., Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and mak

to Schedule 13G

EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

PMC / PharMerica Corp. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 Pharmerica Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2017 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer

Exhibit 99.1 PharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer LOUISVILLE, Ky. – January 31, 2017 – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced the appointment of Robert E. Dries as Executive Vice President and Chief Financial Officer, effec

PharMerica Announces Expansion of Existing Credit Facility, Increasing Borrowing Capacity by $150 Million

Exhibit 99.1 PharMerica Announces Expansion of Existing Credit Facility, Increasing Borrowing Capacity by $150 Million LOUISVILLE, Ky. ? Dec. 15, 2016 ? PharMerica Corporation (?PharMerica? or the ?Company?) (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that it has successfully amended its existing credit a

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission

PharMerica ESP

December 15, 2016 Mr. Craig Arakawa Accounting Branch Chief Office of Beverages, Apparel and Mining Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Mail Stop 3561 Re: PharMerica Company Form 10-K for the Year Ended December 31, 2015 Filed February 26, 2016 Response dated November 14, 2016 File No. 001-33380 Dear Mr. Araka

PharMerica ESP

November 14, 2016 Mr. Craig Arakawa Accounting Branch Chief Office of Beverages, Apparel and Mining Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Mail Stop 3561 Re: PharMerica Corporation Form 10-K for the Year Ended December 31, 2015 Filed February 26, 2016 File No. 001-33380 Dear Mr. Arakawa: This letter responds to a

PHARMERICA REPORTS THIRD QUARTER 2016 RESULTS Expects Strong Fourth Quarter 2016 Results Preliminary 2017 Guidance Within Range of Analysts' Average Expectations Company Revises 2016 Guidance

Contact: Greg S. Weishar Chief Executive Officer (502) 627-7950 PHARMERICA REPORTS THIRD QUARTER 2016 RESULTS Expects Strong Fourth Quarter 2016 Results Preliminary 2017 Guidance Within Range of Analysts' Average Expectations Company Revises 2016 Guidance LOUISVILLE, Ky (November 9, 2016) ? PharMerica Corporation (the "Corporation" or the "Company) (NYSE: PMC), a national provider of institutional

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2016 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID W. FROESEL, JR. Search Process Underway to Identify Successor

Exhibit 99.1 PHARMERICA CORPORATION ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID W. FROESEL, JR. Search Process Underway to Identify Successor LOUISVILLE, Ky. – August 9, 2016 – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that David W. Froesel Jr., Executive Vice Pr

PharMerica (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PharMerica PHARMERICA CORPORATION 8-K 8-9-2016 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA REPORTS SECOND QUARTER 2016 RESULTS

Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS SECOND QUARTER 2016 RESULTS Diversified Pharmacy Businesses Exceeding Management's Expectations Reaffirms Annual 2016 Guidance LOUISVILLE, Ky (August 9, 2016) ? PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital an

PharMerica 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

Pharmerica (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS FIRST QUARTER 2016 RESULTS Financial Results Exceed Expectations Strong Cash Flow From Operating Activities Industry Leading Generic Dispensing Rate Increases to Record 86.6% Reaffirms Annual 2016 Guidance

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FIRST QUARTER 2016 RESULTS Financial Results Exceed Expectations Strong Cash Flow From Operating Activities Industry Leading Generic Dispensing Rate Increases to Record 86.6% Reaffirms Annual 2016 Guidance LOUISVILLE, KY (May 6, 2016) – PharMerica Corporatio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION SUMMARY OF 2016 SHORT-TERM INCENTIVE PROGRAM – CEO 2016 SHORT-TERM INCENTIVE PROGRAM

Exhibit 10.33 PHARMERICA CORPORATION SUMMARY OF 2016 SHORT-TERM INCENTIVE PROGRAM – CEO AND 2016 SHORT-TERM INCENTIVE PROGRAM 2016 Short-Term Incentive Program – CEO On March 17, 2016, the Board of Directors of PharMerica Corporation (the "Corporation"), upon recommendation of the Compensation Committee, adopted the 2016 Short-Term Incentive Program (the "CEO STIP") under the PharMerica Corporatio

PHARMERICA CORPORATION SUMMARY OF 2016 LONG-TERM INCENTIVE PROGRAM

Exhibit 10.34 PHARMERICA CORPORATION SUMMARY OF 2016 LONG-TERM INCENTIVE PROGRAM 2016 Long-Term Incentive Program On March 17, 2016, the Board of Directors of the Corporation, upon recommendation of the Compensation Committee, adopted the 2016 Long-Term Incentive Program (the "LTIP") under the Omnibus Plan to provide restricted stock units and performance share unit awards to the Corporation's exe

Pharmerica DEFA14A

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement ? Definitive Additional Materials o Soliciting Material under 240.

Pharmerica DEF 14A

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under 240.

PHARMERICA PROVIDES UPDATE ON AMERISOURCEBERGEN LITIGATION Continues to Pursue Its Case in Court

Exhibit 99.1 PHARMERICA PROVIDES UPDATE ON AMERISOURCEBERGEN LITIGATION Continues to Pursue Its Case in Court LOUISVILLE, Ky., April 4, 2016 - PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today provided an update on its ongoing litigation against AmerisourceBergen Drug Corporation (?ABDC?), the Company?s

Pharmerica PHARMERICA CORP 8-K 4-4-2016 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

Pharmerica PHARMERICA CORP 8-K 3-17-2016 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission F

Pharmerica PHARMERICA CORPORATION 8-K 3-1-2016 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

Pharmerica (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2016 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS Solid Sequential Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted Earnings Per Share Announces Full Year 2016 Guidance

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS Solid Sequential Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted Earnings Per Share Announces Full Year 2016 Guidance LOUISVILLE, Kentucky (February 26, 2016) – PharMerica Corporation (NYSE

List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

PharMerica ESP

February 23, 2016 Mr. Craig Arakawa Accounting Branch Chief Office of Beverages, Apparel and Mining Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Mail Stop 3561 Re: PharMerica Corporation Form 10-K for the Year Ended December 31, 2014 Filed March 2, 2015 Form 10-Q for the Quarter Ended September 30, 2015 Filed November

to Schedule 13G Joint Filing Agreement

EX-99.2 Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 5, 2016 in connection with their beneficial ownership of Pharmerica Corp. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and make

to Schedule 13G

EX-99.1 Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

PharMerica SC 13G/A (Passive Acquisition of More Than 5% of Shares)

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Pharmerica Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

PharMerica ESP

January 22, 2016 Ms. Tia L. Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel and Mining Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Mail Stop 3561 Re: PharMerica Corporation Form 10-K for the Year Ended December 31, 2014 Filed March 2, 2015 Form 10-Q for the Quarter Ended September 30, 2015 Filed

PharMerica ESP

December 29, 2015 Joanna Lam, CPA Division of Corporation Finance United States Securities and Exchange Commission 100 F.

PharMerica ESP

December 8, 2015 Ms. Tia L. Jenkins Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Re: PharMerica Corporation Form 10-K for the Year Ended December 31, 2014 Filed March 2, 2015 Form 10-Q for the Quarter Ended September 30, 2015 Filed November 6, 2015 File No. 001-33380 Dear Ms. Jenkins:

PharMerica PHARMERICA CORPORATION 8-K 11-6-2015 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION MEMORANDUM OF AGREEMENT

U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION MEMORANDUM OF AGREEMENT This Memorandum of Agreement ("Agreement") is entered into by and between the United States Department of Justice, Drug Enforcement Administration (hereinafter "DEA") and PHARMERICA CORPORATION (hereinafter "PMC"), each a "Party" and collectively hereinafter the "Parties". I. APPLICABILITY This Agreement shall be ap

EX-10.28

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS THIRD QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue and Adjusted EBITDA Industry Leading Generic Dispensing Rate Further Increased to Record 86.5% Reaffirms Annual 2015 Guidance

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS THIRD QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue and Adjusted EBITDA Industry Leading Generic Dispensing Rate Further Increased to Record 86.5% Reaffirms Annual 2015 Guidance LOUISVILLE, Kentucky (November 6, 2015) ? PharMerica Corporat

PharMerica PHARMERICA CORPORATION S-8 8-18-2015

As filed with the Securities and Exchange Commission on August 18, 2015 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS SECOND QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue and Adjusted EBITDA Industry Leading Generic Dispensing Rate Increases To Record 86% Reaffirms Annual 2015 Guidance

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS SECOND QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue and Adjusted EBITDA Industry Leading Generic Dispensing Rate Increases To Record 86% Reaffirms Annual 2015 Guidance LOUISVILLE, Kentucky (August 7, 2015) ? PharMerica Corporation (NYSE:

PharMerica PHARMERICA CORP 8-K 6-19-2015 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PharMerica Enters into Voluntary Settlement Agreement

Exhibit 99.1 PharMerica Enters into Voluntary Settlement Agreement LOUISVILLE, Ky.-(BUSINESS WIRE)-May 14, 2015- PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, and oncology pharmacy services, today announced that it has reached a voluntary settlement with the Department of Justice (DOJ) and with the Drug Enforcement Agency (DEA) related to a previ

PHARMERICA CORPORATION SUMMARY OF 2015 LONG-TERM INCENTIVE PROGRAM

Exhibit 10.27 PHARMERICA CORPORATION SUMMARY OF 2015 LONG-TERM INCENTIVE PROGRAM 2015 Long-Term Incentive Program On March 19, 2015, the Board of Directors of the Corporation, upon recommendation of the Compensation Committee, adopted the 2015 Long-Term Incentive Program (the ?LTIP?) under the Omnibus Plan to provide restricted stock units and performance share unit awards to the Corporation?s exe

PHARMERICA CORPORATION SUMMARY OF 2015 SHORT-TERM INCENTIVE PROGRAM – CEO 2015 SHORT-TERM INCENTIVE PROGRAM

Exhibit 10.26 PHARMERICA CORPORATION SUMMARY OF 2015 SHORT-TERM INCENTIVE PROGRAM ? CEO AND 2015 SHORT-TERM INCENTIVE PROGRAM 2015 Short-Term Incentive Program ? CEO On March 19, 2015, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2015 Short-Term Incentive Program (the ?CEO STIP?) under the PharMerica Corporatio

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d922119d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Inc

PHARMERICA REPORTS FIRST QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted Earnings Per Share Reaffirms Annual 2015 Guidance

EX-99.1 Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FIRST QUARTER 2015 RESULTS Solid Year Over Year Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted Earnings Per Share Reaffirms Annual 2015 Guidance LOUISVILLE, Kentucky (May 7, 2015) – PharMerica Corporation (NYSE: PMC), a na

PRIME VENDOR AGREEMENT

Exhibit 10.25 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. PRIME VENDOR AGREEMENT This Prime Vendor Agreement (the ?Agreement?) is effective April 1, 2015 (the ?Effective Date?) between PharMerica Corporation located at 1901 Campus Place, Louisville, Kentucky 40299

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PharMerica DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under 240.

PharMerica DEFA14A

DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under 240.

Amerita Announces Planned Transition of President and Chief Executive Officer

Exhibit 99.1 Amerita Announces Planned Transition of President and Chief Executive Officer LOUISVILLE, Ky.-(BUSINESS WIRE)-Mar. 27, 2015- Amerita, Inc., a wholly owned subsidiary of PharMerica Corporation (NYSE:PMC), today announced that Jim Glynn, President and Chief Executive Officer of Amerita, will resign from his positions, effective July 3, 2015, in order to devote more time to his family. A

PharMerica PHARMERICA CORP 8-K 3-27-2015 (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

PHARMERICA CORPORATION SUMMARY OF 2014 LONG-TERM INCENTIVE PROGRAM

Exhibit 10.24 PHARMERICA CORPORATION SUMMARY OF 2014 LONG-TERM INCENTIVE PROGRAM 2014 Long-Term Incentive Program On March 11, 2014, the Board of Directors of the Corporation, upon recommendation of the Compensation Committee, adopted the 2014 Long-Term Incentive Program (the ?LTIP?) under the Omnibus Plan to provide, restricted stock units and performance share unit awards to the Corporation?s ex

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2015 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION SUMMARY OF 2014 SHORT-TERM INCENTIVE PROGRAM – CEO 2014 SHORT-TERM INCENTIVE PROGRAM

Exhibit 10.23 PHARMERICA CORPORATION SUMMARY OF 2014 SHORT-TERM INCENTIVE PROGRAM ? CEO AND 2014 SHORT-TERM INCENTIVE PROGRAM 2014 Short-Term Incentive Program ? CEO On March 11, 2014, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2014 Short-Term Incentive Program (the ?CEO STIP?) under the PharMerica Corporatio

PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2014 RESULTS Results for 2014 Transitional Year Exceed Expectations Solid Sequential Quarterly Improvement in Revenue, Gross Profit and Adjusted EBITDA New Drug Wholesale Distribution Agreement Provides

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2014 RESULTS Results for 2014 Transitional Year Exceed Expectations Solid Sequential Quarterly Improvement in Revenue, Gross Profit and Adjusted EBITDA New Drug Wholesale Distribution Agreement Provides Operating and Financial Cl

to Schedule 13G Joint Filing Agreement

EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 13, 2015 in connection with their beneficial ownership of Pharmerica Corp. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and mak

to Schedule 13G

EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

PMC / PharMerica Corp. / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Pharmerica Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: This Sche

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

PMC / PharMerica Corp. CORRESP - -

Thomas A. Caneris Senior Vice President and General Counsel January 8, 2015 Jeffrey P. Riedler, Assistant Director Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Re: PharMerica Corporation Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 28, 2014 File No. 001-33380 Dear Mr. Riedler: This letter respon

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commissio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS THIRD QUARTER 2014 RESULTS

Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS THIRD QUARTER 2014 RESULTS Company Reports Solid Sequential Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted EPS Successfully Executing Strategic and Operational Initiatives to Drive Long-Term Growth and Value Creation Raises 2014 Guidance LOUIS

CREDIT AGREEMENT dated as of September 17, 2014 PHARMERICA CORPORATION, as Borrower THE LENDERS PARTY HERETO BANK OF AMERICA, N.A., as Administrative Agent CITIBANK, N.A., COMPASS BANK, MUFG UNION BANK, N.A., SUNTRUST BANK U.S. BANK, NATIONAL ASSOCIA

EXECUTION VERSION Exhibit 10.32 CREDIT AGREEMENT dated as of September 17, 2014 among PHARMERICA CORPORATION, as Borrower THE LENDERS PARTY HERETO and BANK OF AMERICA, N.A., as Administrative Agent CITIBANK, N.A., COMPASS BANK, MUFG UNION BANK, N.A., SUNTRUST BANK and U.S. BANK, NATIONAL ASSOCIATION, as Co-Documentation Agents MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED and J.P. MORGAN SECU

PHARMERICA ANNOUNCES NEW SENIOR SECURED CREDIT AGREEMENT New Agreement Expands Committed and Uncommitted Credit Capacity by $200 Million and Reduces Interest Rate by 75 Basis Points PharMerica has a Strong Financial Foundation and is Well Positioned

Exhibit 99.1 FOR IMMEDIATE DISTRIBUTION PHARMERICA ANNOUNCES NEW SENIOR SECURED CREDIT AGREEMENT New Agreement Expands Committed and Uncommitted Credit Capacity by $200 Million and Reduces Interest Rate by 75 Basis Points PharMerica has a Strong Financial Foundation and is Well Positioned to Capitalize on Growth Opportunities LOUISVILLE, Ky., September 19, 2014 - PharMerica Corporation (NYSE: PMC)

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

SUPPLEMENTAL INFORMATION PURSUANT TO RULE 3(A) OF THE RULES OF THE COURT OF CHANCERY

Exhibit 99.2 SUPPLEMENTAL INFORMATION PURSUANT TO RULE 3(A) OF THE RULES OF THE COURT OF CHANCERY The information contained herein is for the use by the Court for statistical and administrative purposes only. Nothing stated herein shall be deemed an admission by or binding upon any party. 1. Caption of Case: AmerisourceBergen Drug Corporation, Plaintiff, v. PharMerica Corporation, Pharmacy Corpora

PHARMERICA RAISES 2014 EARNINGS GUIDANCE Announces Acquisition of Three Institutional Pharmacies in Texas, Expanding PharMerica’s Presence in the State Reaches Goal of Completing Acquisitions Generating Approximately $100 Million of Annualized Sales

Exhibit 99.1 PHARMERICA RAISES 2014 EARNINGS GUIDANCE Announces Acquisition of Three Institutional Pharmacies in Texas, Expanding PharMerica’s Presence in the State Reaches Goal of Completing Acquisitions Generating Approximately $100 Million of Annualized Sales in 2014 Comments on AmerisourceBergen Contract LOUISVILLE, Ky., September 10, 2014 - PharMerica Corporation (NYSE: PMC), a national provi

VERIFIED COMPLAINT

Exhibit 99.3 NO. 14CI004682 JEFFERSON CIRCUIT COURT DIVISION TEN (10) JUDGE JEFFERSON CIRCUIT COURT DIVISION TEN (10) PHARMERICA CORPORATION PLAINTIFF v. AMERISOURCEBERGEN DRUG CORPORATION DEFENDANT Serve: CT Corporation System 306 W. Main Street Suite 512 Frankfort, KY 40601 VERIFIED COMPLAINT Plaintiff, PharMerica Corporation ("PharMerica"), brings this action for breach of contract and a declar

Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incor

Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commissio

PHARMERICA RAISES 2014 EARNINGS GUIDANCE Announces Acquisition of Three Institutional Pharmacies in Texas, Expanding PharMerica’s Presence in the State Reaches Goal of Completing Acquisitions Generating Approximately $100 Million of Annualized Sales

Exhibit 99.1 PHARMERICA RAISES 2014 EARNINGS GUIDANCE Announces Acquisition of Three Institutional Pharmacies in Texas, Expanding PharMerica’s Presence in the State Reaches Goal of Completing Acquisitions Generating Approximately $100 Million of Annualized Sales in 2014 Comments on AmerisourceBergen Contract LOUISVILLE, Ky., September 10, 2014 - PharMerica Corporation (NYSE: PMC), a national provi

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT by and between PharMerica Corporation and (hereinafter the "Company"), and David W.

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT THIS AGREEMENT by and between PharMerica Corporation and (hereinafter the "Company"), and James D.

PHARMERICA REPORTS SECOND QUARTER 2014 RESULTS Successfully Executing Strategic and Operational Initiatives to Drive Long-Term Growth and Value Creation Company Reports Solid Sequential Improvement in Gross Profit, Adjusted EBITDA Margin and Adjusted

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS SECOND QUARTER 2014 RESULTS Successfully Executing Strategic and Operational Initiatives to Drive Long-Term Growth and Value Creation Company Reports Solid Sequential Improvement in Gross Profit, Adjusted EBITDA Margin and Adjusted Diluted EPS Raises 2014 Gu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2014 PHARMERICA CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission Fi

PMC / PharMerica Corp. / HEARTLAND ADVISORS INC - AMENDMENT NO. 4 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* PHARMERICA CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) May 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

- PHARMERICA CORPORATION S-8 5-15-2014

UNITED STATES SECURITIES EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 87-0792558 (I.R.S. Employer Identification No.) 1901 Campus Place Louisville, Kentucky 40299 (Address of principal ex

Financial Statements and Exhibits, Results of Operations and Financial Condition - PHARMERICA CORPORATION 8-K 5-1-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS FIRST QUARTER 2014 RESULTS Company Reports Solid Revenues, Adjusted EBITDA and Adjusted Diluted Earnings Per Share; Updates 2014 Guidance Successfully Executing Strategic and Operational Initiatives to Drive Long-Term Growth and Va

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FIRST QUARTER 2014 RESULTS Company Reports Solid Revenues, Adjusted EBITDA and Adjusted Diluted Earnings Per Share; Updates 2014 Guidance Successfully Executing Strategic and Operational Initiatives to Drive Long-Term Growth and Value Creation LOUISVILLE, Ke

- DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under 240.

- DEFINITIVE ADDITIONAL MATERIALS

Definitive Additional Materials SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under 240.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - PHARMERICA CORPORATION 8-K 3-11-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2014 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission F

AMENDED AND RESTATED BY-LAWS PHARMERICA CORPORATION As Amended March 11, 2014 ARTICLE I

Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF PHARMERICA CORPORATION As Amended March 11, 2014 ARTICLE I Stockholders Section 1.01. Annual Meetings. The annual meeting of the stockholders of the Corporation for the election of Directors and for the transaction of such other business as properly may come before such meeting shall be held at such place, either within or without the State of Delaware,

FORM OF MUTUAL RELEASE OF CLAIMS

Exhibit 10.1 February 27, 2014 Mr. Gregory Weishar 14505 Clearlake Place Louisville, Kentucky 40245 Dear Greg: This letter agreement (the “Letter Agreement”), originally entered into on September 29, 2010 by PharMerica Corporation (“Company”) is amended and restated in its entirety as set forth herein, effective on the date first set forth above, and sets forth the terms and conditions of your emp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - PHARMERICA CORP 8-K 2-27-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2014 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commissio

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition - PHARMERICA CORPORATION 8-K 2-28-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2014 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2013 RESULTS Company Achieved Record Adjusted Earnings Per Share, Cash Flows from Operating Activities and Adjusted EBITDA in 2013 Specialty Infusion and Oncology Businesses Expected to Generate Annual

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS FOURTH QUARTER AND FULL YEAR 2013 RESULTS Company Achieved Record Adjusted Earnings Per Share, Cash Flows from Operating Activities and Adjusted EBITDA in 2013 Specialty Infusion and Oncology Businesses Expected to Generate Annual Revenues of Approximately $

PMC / PharMerica Corp. / HARRIS ASSOCIATES L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu

PMC / PharMerica Corp. / VANGUARD GROUP INC Passive Investment

pharmericacorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: PharMerica Corp Title of Class of Securities: Common Stock CUSIP Number: 71714F104 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to de

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

PMC / PharMerica Corp. / HEARTLAND ADVISORS INC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) PHARMERICA CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31st, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

JOINT FILING AGREEMENT

EXHIBIT 1 – JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing with the other reporting person of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

THOMSON REUTERS STREETEVENTS |

Exhibit 99.1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2014 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2014 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - PHARMERICA CORPORATION 8-K 1-3-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2014 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Results of Operations and Financial Condition - PHARMERICA CORP 8-K 11-5-2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

EMPLOYMENT AGREEMENT

Exhibit 10.40 EMPLOYMENT AGREEMENT THIS AGREEMENT by and between PharMerica Corporation and (hereinafter the ?Company?), and David W. Froesel, Jr. (the ?Executive?) is effective as of August 1, 2013 (?Start Date"); WHEREAS, the Company desires to employ the Executive, effective as of the Start Date, as the Executive Vice President, Chief Financial Officer and Treasurer of the Company, and the Exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS RECORD RESULTS FOR THE THIRD QUARTER OF 2013 Company Achieves Record Adjusted Diluted Earnings Per Share Of $0.49 For The Third Quarter And Establishes A Record Of $1.39 On A Nine Month Year-To-Date Basis Company Achieves Record Ca

Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS RECORD RESULTS FOR THE THIRD QUARTER OF 2013 Company Achieves Record Adjusted Diluted Earnings Per Share Of $0.49 For The Third Quarter And Establishes A Record Of $1.39 On A Nine Month Year-To-Date Basis Company Achieves Record Cash Flows From Operating Act

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA APPOINTS DAVID W. FROESEL, JR. AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER

EX-99.1 Exhibit 99.1 PHARMERICA APPOINTS DAVID W. FROESEL, JR. AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER Louisville, Kentucky (August 2, 2013) – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that it has appointed David W. Froesel, Jr. as Executive Vice Preside

PHARMERICA REPORTS RESULTS FOR THE SECOND QUARTER OF 2013 Adjusted Diluted Earnings Per Share Increases 26% to $0.44 Adjusted EBITDA Increases 26% to $33.7 Million Adjusted EBITDA Margin Increases 200 Basis Points to 7.8% Company Maintains Industry L

EX-99.1 Exhibit 99.1 Contact: David W. Froesel, Jr. Executive Vice President, Chief Financial Officer and Treasurer (502) 627-7950 PHARMERICA REPORTS RESULTS FOR THE SECOND QUARTER OF 2013 Adjusted Diluted Earnings Per Share Increases 26% to $0.44 Adjusted EBITDA Increases 26% to $33.7 Million Adjusted EBITDA Margin Increases 200 Basis Points to 7.8% Company Maintains Industry Leading Generic Disp

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Comm

Submission of Matters to a Vote of Security Holders - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Comm

- DEFINTITIVE ADDITIONAL MATERIALS

Defintitive Additional Materials SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under 240.

Regulation FD Disclosure - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2013 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

FIRST AMENDMENT TO THE AMENDED AND RESTATED PRIME VENDOR AGREEMENT FOR LONG-TERM CARE PHARMACIES

Exhibit 10.33 [***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. THREE ASTERISKS DENOTE SUCH OMISSIONS. FIRST AMENDMENT TO THE AMENDED AND RESTATED PRIME VENDOR AGREEMENT FOR LONG-TERM CARE PHARMACIES This First Amendment (?First Amendment?) is entered into as of Januar

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA CORPORATION SUMMARY OF 2013 SHORT-TERM INCENTIVE PROGRAM – CEO 2013 SHORT-TERM INCENTIVE PROGRAM

Exhibit 10.38 PHARMERICA CORPORATION SUMMARY OF 2013 SHORT-TERM INCENTIVE PROGRAM ? CEO AND 2013 SHORT-TERM INCENTIVE PROGRAM 2013 Short-Term Incentive Program ? CEO On March 4, 2013, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2013 Short-Term Incentive Program (the ?CEO STIP?) under the PharMerica Corporation

PHARMERICA REPORTS RESULTS FOR THE FIRST QUARTER OF 2013 Company Achieves Record Adjusted Diluted Earnings Per Share of $0.46 Company Achieves Record Adjusted EBITDA of $34.6 Million Company Achieves Record Adjusted EBITDA Margin of 7.9% Company Main

EX-99.1 Exhibit 99.1 Contact: David W. Froesel, Jr. Interim Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS RESULTS FOR THE FIRST QUARTER OF 2013 Company Achieves Record Adjusted Diluted Earnings Per Share of $0.46 Company Achieves Record Adjusted EBITDA of $34.6 Million Company Achieves Record Adjusted EBITDA Margin of 7.9% Company Maintains Industry Leading Generic Dispensing Rate of 8

PHARMERICA CORPORATION SUMMARY OF 2013 LONG-TERM INCENTIVE PROGRAM

Exhibit 10.39 PHARMERICA CORPORATION SUMMARY OF 2013 LONG-TERM INCENTIVE PROGRAM 2013 Long-Term Incentive Program On March 4, 2013, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2013 Long-Term Incentive Program (the ?LTIP?) under the PharMerica Corporation 2007 Omnibus Incentive Plan, as amended (the ?Omnibus Pl

- DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under 240.

PharMerica Appoints David Froesel, Jr. as Interim Chief Financial Officer

EX-99.1 Exhibit 99.1 PharMerica Appoints David Froesel, Jr. as Interim Chief Financial Officer Company Initiates Search for Permanent CFO LOUISVILLE, Ky.—(BUSINESS WIRE)—Apr. 12, 2013— PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that the Company has appointed David W. Froesel, Jr. a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2013 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2013 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

PMC / PharMerica Corp. / HARRIS ASSOCIATES L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* PHARMERICA (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

PMC / PharMerica Corp. / VANGUARD GROUP INC Passive Investment

pharmericacorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: PharMerica Corp Title of Class of Securities: Common Stock CUSIP Number: 71714F104 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to de

PMC / PharMerica Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PHARMERICA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA REPORTS RESULTS FOR THE FOURTH QUARTER OF 2012 AND YEAR ENDED DECEMBER 31, 2012 Full Year Adjusted EBITDA Increases 5.7% Full Year Adjusted Diluted Earnings Per Share Increases 5.8% Full Year Adjusted EBITDA Margin Increases to 5.7% Compan

EX-99.1 Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS RESULTS FOR THE FOURTH QUARTER OF 2012 AND YEAR ENDED DECEMBER 31, 2012 Full Year Adjusted EBITDA Increases 5.7% Full Year Adjusted Diluted Earnings Per Share Increases 5.8% Full Year Adjusted EBITDA Margin Increases to 5.7% Company Announces 2013 Earnings Guidanc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

EMPLOYMENT AGREEMENT

Exhibit 10.32 EMPLOYMENT AGREEMENT THIS AGREEMENT by and between PharMerica Corporation and (hereinafter the ?Company?), and Mark Lindemoen (the ?Executive?) is effective as of September 27, 2012 (?Start Date?); WHEREAS, the Company desires to employ the Executive, effective as of the Start Date, as the Senior Vice President of Sales and Client Services of the Company, and the Executive desires to

Entry into a Material Definitive Agreement - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2013 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION NAMES PATRICK G. LEPORE TO ITS BOARD OF DIRECTORS

Press Release Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA CORPORATION NAMES PATRICK G. LEPORE TO ITS BOARD OF DIRECTORS LOUISVILLE, Kentucky (January 14, 2013) – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

PHARMERICA REPORTS RESULTS FOR THE THIRD QUARTER OF 2012 AND NINE MONTHS ENDED SEPTEMBER 30, 2012 Year to Date Adjusted EBITDA Increases 8% Year to Date Adjusted Diluted Earnings Per Share Increase 9% Quarterly Generic Dispensing Rate Exceeds 84% Com

Press Release of PharMerica Corporation dated November 1, 2012 Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS RESULTS FOR THE THIRD QUARTER OF 2012 AND NINE MONTHS ENDED SEPTEMBER 30, 2012 Year to Date Adjusted EBITDA Increases 8% Year to Date Adjusted Diluted Earnings Per Share Increase 9% Quarterly Generic Dispensin

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

-

Correspondence Letter October 15, 2012 Frank Wyman Division of Corporation Finance United States Securities and Exchange Commission 100 F.

-

Correspondence Letter September 11, 2012 Jim B. Rosenberg Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549-4720 Re: PharMerica Corporation Form 10-K for the Fiscal Year Ended December 31, 2011 Filed February 9, 2012 File No. 001-33380 Dear Mr. Rosenberg: This letter responds to a comment letter received from the United States S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA REPORTS RESULTS FOR THE SECOND QUARTER OF 2012 AND SIX MONTHS ENDED JUNE 30, 2012 Year to Date Adjusted EBITDA Increases 11% Year to Date Adjusted Diluted Earnings Per Share Increases 13% Year to Date Cash Flow from Operations Increases $5

Press Release of PharMerica Corporation dated August 2, 2012 Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS RESULTS FOR THE SECOND QUARTER OF 2012 AND SIX MONTHS ENDED JUNE 30, 2012 Year to Date Adjusted EBITDA Increases 11% Year to Date Adjusted Diluted Earnings Per Share Increases 13% Year to Date Cash Flow from Ope

Financial Statements and Exhibits, Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION ANNOUNCES $25 MILLION SHARE PURCHASE PROGRAM

Press Release of PharMerica Corporation dated July 2, 2012 Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA CORPORATION ANNOUNCES $25 MILLION SHARE PURCHASE PROGRAM LOUISVILLE, Kentucky (July 2, 2012) – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, t

Submission of Matters to a Vote of Security Holders - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Comm

Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2012 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION SUMMARY OF 2012 SHORT-TERM INCENTIVE PROGRAM – CEO 2012 SHORT-TERM INCENTIVE PROGRAM

Exhibit 10.38 PHARMERICA CORPORATION SUMMARY OF 2012 SHORT-TERM INCENTIVE PROGRAM ? CEO AND 2012 SHORT-TERM INCENTIVE PROGRAM 2012 Short-Term Incentive Program ? CEO On January 18, 2012, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2012 Short-Term Incentive Program (the ?CEO STIP?) under the PharMerica Corporat

PHARMERICA REPORTS RESULTS FOR THE FIRST QUARTER OF 2012 1Q Adjusted EBITDA Increases 30% 1Q Adjusted Earnings Per Share Increases 50% Company Maintains 2012 Earnings Guidance

Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS RESULTS FOR THE FIRST QUARTER OF 2012 1Q Adjusted EBITDA Increases 30% 1Q Adjusted Earnings Per Share Increases 50% Company Maintains 2012 Earnings Guidance LOUISVILLE, Kentucky (May 2, 2012) – PharMerica Corporation (NYSE: PMC), a national provider of institutional pharm

Financial Statements and Exhibits, Results of Operations and Financial Condition - PHARMERICA CORPORATION 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PHARMERICA CORPORATION SUMMARY OF 2012 LONG-TERM INCENTIVE PROGRAM

Exhibit 10.39 PHARMERICA CORPORATION SUMMARY OF 2012 LONG-TERM INCENTIVE PROGRAM 2012 Long-Term Incentive Program On January 18, 2012, the Board of Directors of PharMerica Corporation (the ?Corporation?), upon recommendation of the Compensation Committee, adopted the 2012 Long-Term Incentive Program (the ?LTIP?) under the PharMerica Corporation 2007 Omnibus Incentive Plan, as amended (the ?Omnibus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

- DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under 240.

- DEFINITIVE ADDITIONAL MATERIALS

Definitive Additional Materials SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under 240.

AMENDMENT NO. 1 TO RIGHTS AGREEMENT

Amendment No. 1 to Rights Agreement, dated as of March 28, 2012 Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This Amendment No. 1 to Rights Agreement (this “Amendment”), dated as of March 28, 2012, between PharMerica Corporation, a Delaware corporation (the “Company”), and Computershare Shareowner Services LLC (f/k/a Mellon Investor Services LLC), a New Jersey limited liability company, as Righ

- FORM 8-A/A

FORM 8-A/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 887-0792558 (State of incorporation or organization) (I.R.S. Employer Identificat

CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK PHARMERICA CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware

Certificate of Elimination for PharMerica Corporation Exhibit 3.1 CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF PHARMERICA CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware PharMerica Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), in accordance with the prov

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

8-K 1 d328249d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2012 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of

OMNICARE ANNOUNCES EXPIRATION OF ITS TENDER OFFER TO ACQUIRE PHARMERICA

Exhibit (a)(5)(S) news release OMNICARE ANNOUNCES EXPIRATION OF ITS TENDER OFFER TO ACQUIRE PHARMERICA COVINGTON, Ky.

- AMENDMENT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 17) PHARMERICA CORPORATION (Name of Subject Company (Issuer)) PHILADELPHIA ACQUISITION SUB, INC. OMNICARE, INC. (Names of Filing Persons (Offerors)) Common Stock, Par Value $0.01 Per Share (Title of Cl

PMC / PharMerica Corp. / HARRIS ASSOCIATES L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* PHARMERICA (Name of Issuer) Common Stock (Title of Class of Securities) 71714F104 (CUSIP Number) December 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

PMC / PharMerica Corp. / TIG Advisors, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

PMC / PharMerica Corp. / TIG Advisors, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition - PHARMERICA CORPORATION 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2012 PHARMERICA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33380 87-0792558 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS STRONG RESULTS FOR THE FOURTH QUARTER OF 2011 AND YEAR ENDED DECEMBER 31, 2011 4Q Adjusted EBITDA Increases 55% 4Q Adjusted Earnings Per Share I

EX-99.1 2 a50163707ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Michael J. Culotta Executive Vice President and Chief Financial Officer (502) 627-7475 PHARMERICA REPORTS STRONG RESULTS FOR THE FOURTH QUARTER OF 2011 AND YEAR ENDED DECEMBER 31, 2011 4Q Adjusted EBITDA Increases 55% 4Q Adjusted Earnings Per Share Increase 75% 4Q Adjusted EBITDA Margin Increases to 5.6% Company Announces 2012 Earning

PMC / PharMerica Corp. / VANGUARD GROUP INC Passive Investment

pharmericacorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:2 )* Name of issuer: PharMerica Corp Title of Class of Securities: Common Stock CUSIP Number: 71714F104 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

Exhibit 21.1 List of Subsidiaries Name of Entity Place of Incorporation PharMerica Holdings, Inc. Delaware

OMNICARE COMMENTS ON FTC POSITION

Exhibit (a)(5)(R) news release OMNICARE COMMENTS ON FTC POSITION COVINGTON, Ky., January 27, 2012 — Omnicare, Inc. (NYSE:OCR) today issued the following statement responding to the Federal Trade Commission’s (FTC) split (3 to 1) decision to issue an administrative complaint to block Omnicare’s offer to purchase all outstanding shares of PharMerica Corporation (NYSE: PMC) common stock for $15.00 pe

- AMENDMENT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 16) PHARMERICA CORPORATION (Name of Subject Company (Issuer)) PHILADELPHIA ACQUISITION SUB, INC. OMNICARE, INC. (Names of Filing Persons (Offerors)) Common Stock, Par Value $0.01 Per Share (Title of Cl

- AMENDMENT NO. 10 TO SCHEDULE 14D-9

AMENDMENT NO. 10 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) PHARMERICA CORPORATION (Name of Subject Company) PHARMERICA CORPORATION (Names of Persons Filing Statement) Common stock, $0.01 par value (Title of Class of Securities) 7171

PHARMERICA COMMENTS ON FTC DECISION TO BLOCK OMNICARE’S HOSTILE TENDER OFFER

PRESS RELEASE OF THE COMPANY, DATED JANUARY 30, 2012 Exhibit (a)(18) Contacts: Michael J.

- AMENDMENT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) PHARMERICA CORPORATION (Name of Subject Company (Issuer)) PHILADELPHIA ACQUISITION SUB, INC. OMNICARE, INC. (Names of Filing Persons (Offerors)) Common Stock, Par Value $0.01 Per Share (Title of Cl

OMNICARE EXTENDS TENDER OFFER FOR PHARMERICA UNTIL FEBRUARY 17, 2012

Exhibit (a)(5)(Q) news release OMNICARE EXTENDS TENDER OFFER FOR PHARMERICA UNTIL FEBRUARY 17, 2012 COVINGTON, Ky.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2012 PHARMERICA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33380 87-0792558 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.